Arizona Tribune - BioLargo Protects Its Intellectual Property That Built a National Brand - Pooph's License Was Revoked for Non-Payment and Unauthorized Activities

On September 25, 2025, BioLargo revoked Pooph's license to manufacture, market, and sell products containing BioLargo's technology after Pooph's failure to pay approximately $3.8 million owed for product purchases and license royalties, and the marketing of its products outside the pet industry. This termination followed on BioLargo's prior notice to Pooph that it had ceased delivering products due to Pooph's failure to pay monies owed.

Despite BioLargo's clear and lawful termination of the license, Pooph issued a press release containing allegations that BioLargo strongly denies and will vigorously defend against. The press release further referenced a lawsuit Pooph claims to have filed but has not yet attempted legal service.

"Our technology is the foundation that built the Pooph brand and made it successful," said Dennis P. Calvert, President and CEO of BioLargo. "BioLargo's patented odor control technology, developed and perfected over years of research, is what made Pooph possible. We acted decisively to revoke their license when Pooph failed to meet its financial obligations and stepped outside the agreed boundaries of our contract."

BioLargo emphasizes that its focus now is on protecting its intellectual property and redeploying its technology with new partners that share its commitment to quality, transparency, and integrity.

"We are confident that the facts will show that BioLargo acted appropriately and in good faith at all times," Calvert added. "Our technology continues to demonstrate its superior performance, and we look forward to working with responsible partners who honor their commitments."

BioLargo's leadership underscored that the Pooph dispute affects only that specific license and will have negligible effect on BioLargo's other business units or growth strategy. The company remains financially stable and focused on expanding its technology applications across consumer, industrial, and environmental markets, including health care.

"BioLargo's mission and long-term business trajectory remain strong," said Calvert. "We're focused on protecting our stockholders' interests, advancing our science, and continuing to bring our technology to market through new and better partnerships."

About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc

View the original press release on ACCESS Newswire

T.Sanchez--AT